Catalent, Novo Holdings

Novo Holdings closes $16.5 billion buyout of contract manufacturer Catalent
Novo Holdings, the controlling shareholder of Novo Nordisk, on Wednesday sealed its $16.5 billion deal for Catalent, as the Danish drugmaker looks to boost supplies of its widely popular weight-loss drug Wegovy.
Novo Holdings says its acquisition of Catalent is complete.
Indications are that Novo will be investing in both the plant and the community,” an Indiana University professor said.
Novo Holdings Completes Acquisition of Catalent
Catalent, Inc. ("Catalent"), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S ("Novo Holdings"), a global life sciences investment firm,
Novo Holdings completes $16.5 billion takeover of Catalent
Novo Holdings has completed its $16.5 billion acquisition of Catalent, the contract drug manufacturer said on Wednesday, days after the companies disclosed that all regulatory conditions to close the deal were fulfilled.
Novo Holdings set to close $16.5B Catalent buy in 'coming days' after deal clears antitrust hurdles
After clearing all regulatory hurdles associated with its proposed buyout of CDMO Catalent, Novo Holdings is nearly ready to unwrap its $16.5 billion present just in time for the holidays.
Novo Holdings Gets FTC’s Go-Ahead for Contentious $16.5B Catalent Acquisition
Now that they’ve received the go-signal from both U.S. and EU anti-trust regulators, Novo Holdings and Catalent expect to wrap up their deal in the coming days.
Novo Holdings completes purchase of Catalent
Novo Holdings said that it completed it's $16.5 billion acquisition of Catalent Inc. (NYSE:CTLT). Shortly following the completion of the deal, Novo Nordisk A/S (NVO)  will acquire from Novo Holdings Catalent’s three fill-finish sites located in Anagni,
Business Insider5h
Novo Holdings Acquires Catalent In $16.5 Bln Cash Deal
(RTTNews) - Wednesday, Novo Holdings A/S completed the acquisition of Catalent, Inc. (CTLT), a global contract development and manufacturing organization, in an all-cash transaction worth ...
FierceBiotech5h
Novo Holdings leads SiteOne's $100M series C for non-opioid pain treatments
SiteOne Therapeutics is powering up with $100 million to advance its early pipeline of non-opioid therapeutics that target ...
pharmaphorum16h
Novo Holdings leads $100m round for novel painkiller biotech
The Series C – which was led by Novo Nordisk's parent company Novo Holdings – follows a $15 million second round for ...
STAT2d
Pharmalittle: We’re reading about Novo Holdings proceeding with Catalent deal, Sanofi threatened with sanctions, and more
Novo Holdings can proceed with its planned $16.5 billion acquisition of Catalent after U.S. regulators declined to challenge ...
MM&M2d
Novo Holdings’ $16.5B deal for Catalent clears last regulatory hurdle
Novo Holdings is on track to acquire Catalent, a global contract development and manufacturing organization, in a $16.5 ...
Indiana Daily Student3d
Novo’s takeover of Catalent set to proceed after FTC declines to challenge deal
Novo Holdings will proceed with its $16.5 billion acquisition of Catalent, the companies announced Saturday, after the ...
Barron's on MSN1d
Novo’s New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way.
The end of Novo Nordisk’s supply problems could bring new headaches for the rest of the pharmaceutical industry, which now ...
Healthy Returns: A huge deal to boost Novo Nordisk's manufacturing is one step closer to closing
Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...